Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 Dec;90(6):2543–2547. doi: 10.1172/JCI116148

Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant.

J A Waters 1, M Kennedy 1, P Voet 1, P Hauser 1, J Petre 1, W Carman 1, H C Thomas 1
PMCID: PMC443413  PMID: 1281839

Abstract

A previous study (Carman, W. F., A. R. Zanetti, P. Karayiannis, J. A. Waters, G. Manzillo, E. Tanzi, A. J. Zuckerman, and H. C. Thomas. 1990. Lancet. 336:325-329) demonstrated a variant hepatitis B surface antigen (HBsAg) in a vaccinated child born to a hepatitis B virus-infected mother. A substitution of arginine for glycine at amino acid 145 in HBsAg was observed. In this study the effect of this substitution on the common "a" determinant of this protein, against which protective immunity is directed, is investigated. Using recombinant HBsAg with and without the amino acid substitution, the binding of monoclonal antibodies that recognize different epitopes of the "a" determinant, was shown to be destroyed by the presence of arginine at amino acid 145. In convalescent and vaccinee sera, antibody binding to HBsAg was not inhibited by the variant HBsAg. Immunization with the variant HBsAg, although eliciting a high titer antibody that recognized the variant, produced a low titer of antibody recognizing the native protein. Studies in mice demonstrate that the immunogenicity of the variant protein is also substantially altered. The data presented here demonstrate that this variant evades the known protective anti-HBs response and lends support to the suggestion that this mutation arose as the result of immune pressure.

Full text

PDF
2543

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashton-Rickardt P. G., Murray K. Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immunodominant a region. J Med Virol. 1989 Nov;29(3):196–203. doi: 10.1002/jmv.1890290310. [DOI] [PubMed] [Google Scholar]
  2. Carman W. F., Zanetti A. R., Karayiannis P., Waters J., Manzillo G., Tanzi E., Zuckerman A. J., Thomas H. C. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990 Aug 11;336(8711):325–329. doi: 10.1016/0140-6736(90)91874-a. [DOI] [PubMed] [Google Scholar]
  3. Harford N., Cabezon T., Colau B., Delisse A. M., Rutgers T., De Wilde M. Construction and characterization of a Saccharomyces cerevisiae strain (RIT4376) expressing hepatitis B surface antigen. Postgrad Med J. 1987;63 (Suppl 2):65–70. [PubMed] [Google Scholar]
  4. Harford N., Cabezon T., Crabeel M., Simoen E., Rutgers A., De Wilde M. Expression of hepatitis B surface antigen in yeast. Dev Biol Stand. 1983;54:125–130. [PubMed] [Google Scholar]
  5. Imai M., Goto A., Nishioka K., Kurashina S., Miyakawa Y. Antigenicity of reduced and alkylated Australia antigen. J Immunol. 1974 Jan;112(1):416–419. [PubMed] [Google Scholar]
  6. Jilg W., Lorbeer B., Schmidt M., Wilske B., Zoulek G., Deinhardt F. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet. 1984 Nov 24;2(8413):1174–1175. doi: 10.1016/s0140-6736(84)92740-5. [DOI] [PubMed] [Google Scholar]
  7. Koziol D. E., Alter H. J., Kirchner J. P., Holland P. V. The development of HBsAg-positive hepatitis despite the previous existence of antibody to HBsAg. J Immunol. 1976 Dec;117(6):2260–2262. [PubMed] [Google Scholar]
  8. Le Bouvier G. L., Capper R. A., Williams A. E., Pelletier M., Katz A. J. Concurrently circulating hepatitis B surface antigen and heterotypic anti-HBs antibody. J Immunol. 1976 Dec;117(6):2262–2264. [PubMed] [Google Scholar]
  9. Mishiro S., Imai M., Takahashi K., Machida A., Gotanda T., Miyakawa Y., Mayumi M. A 49,000-dalton polypeptide bearing all antigenic determinants and full immunogenicity of 22-nm hepatitis B surface antigen particles. J Immunol. 1980 Apr;124(4):1589–1593. [PubMed] [Google Scholar]
  10. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]
  11. Wampler D. E., Lehman E. D., Boger J., McAleer W. J., Scolnick E. M. Multiple chemical forms of hepatitis B surface antigen produced in yeast. Proc Natl Acad Sci U S A. 1985 Oct;82(20):6830–6834. doi: 10.1073/pnas.82.20.6830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Waters J. A., Brown S. E., Steward M. W., Howard C. R., Thomas H. C. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res. 1992 Jan;22(1):1–12. doi: 10.1016/0168-1702(92)90085-n. [DOI] [PubMed] [Google Scholar]
  13. Zanetti A. R., Tanzi E., Manzillo G., Maio G., Sbreglia C., Caporaso N., Thomas H., Zuckerman A. J. Hepatitis B variant in Europe. Lancet. 1988 Nov 12;2(8620):1132–1133. doi: 10.1016/s0140-6736(88)90541-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES